Standout Papers

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesy... 2008 2026 2014 2020 742
  1. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT (2008)
    Charles D. Blanke, George D. Demetri et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 2 from Science/Nature 66 standout
Sub-graph 1 of 20

Citing Papers

In-situ-sprayed therapeutic hydrogel for oxygen-actuated Janus regulation of postsurgical tumor recurrence/metastasis and wound healing
2024 Standout
A foundation model for clinician-centered drug repurposing
2024 Standout
2 intermediate papers

Works of Daniela Heinz being referenced

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
2008 Standout

Author Peers

Author Last Decade Papers Cites
Daniela Heinz 54 309 1 632 558 3 752
Christine M. Barnett 72 235 1 508 509 8 714
Michelle Brown 75 319 1 659 606 9 868
C. Tsao 71 290 1 606 551 6 833
Hema Sundar 18 548 2 804 731 6 919
Oddvar M. Sandvik 57 372 4 494 446 10 758
Allen Burke 9 530 756 584 5 830
Salah‐Eddin Al‐Batran 207 321 11 292 581 10 844
José Gaal 136 447 2 134 162 14 756
Annick Van den Abbeele 43 103 1 100 327 9 724
Elisabeth Wehrle 50 126 1 275 233 10 786

All Works

Loading papers...

Rankless by CCL
2026